Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2010-06

AUTHORS

Dafna D Gladman, Philip J Mease, Ernest HS Choy, Christopher T Ritchlin, Renee J Perdok, Eric H Sasso

ABSTRACT

INTRODUCTION: To identify independent predictors of radiographic progression in psoriatic arthritis (PsA) for patients treated with adalimumab or placebo in the Adalimumab Effectiveness in PsA Trial (ADEPT). METHODS: Univariate analyses and multivariate linear regression analyses assessed risk for radiographic progression (change in modified total Sharp score, DeltamTSS>0.5) from baseline to week 24 for C-reactive protein (CRP) and other baseline variables, and for 24-week time-averaged CRP (univariate analysis only). Subanalyses determined mean DeltamTSS for CRP subgroups. Analyses were post hoc, with observed data. RESULTS: One hundred and forty-four adalimumab-treated patients and 152 placebo-treated patients were assessed. Mean CRP was 64% lower by week 2 with adalimumab and essentially unchanged with placebo. Univariate analyses indicated that elevated CRP at baseline and time-averaged CRP were strongly associated with radiographic progression for placebo-treated patients but not for adalimumab-treated patients. Multivariate analysis confirmed that elevated baseline CRP was the only strong independent risk factor for radiographic progression (for CRP>or=1.0 mg/dl: odds ratio=3.28, 95% confidence interval=1.66 to 6.51, P<0.001). Adalimumab treatment reduced risk of progression approximately fivefold. The difference between mean DeltamTSS for adalimumab versus placebo was greatest for patients with baseline CRP>or=2.0 mg/dl (-0.5 vs. 2.6). CONCLUSIONS: Systemic inflammation in PsA, as indicated by elevated baseline CRP, was the only strong independent predictor of radiographic progression. This association was observed predominantly for placebo-treated patients. Adalimumab treatment substantially reduced the overall risk of radiographic progression, and provided greatest radiographic benefit for patients with the greatest CRP concentrations at baseline. TRIAL REGISTRATION: Trial registration: NCT00195689. More... »

PAGES

r113

References to SciGraph publications

  • 2008. Psoriatic Arthritis in PRIMER ON THE RHEUMATIC DISEASES
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1186/ar3049

    DOI

    http://dx.doi.org/10.1186/ar3049

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1013409774

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/20537151


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adalimumab", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibodies, Monoclonal", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibodies, Monoclonal, Humanized", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antirheumatic Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Arthritis, Psoriatic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "C-Reactive Protein", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Disease Progression", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Double-Blind Method", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Linear Models", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Multivariate Analysis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Radiography", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Risk Factors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Treatment Outcome", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "University of Toronto", 
              "id": "https://www.grid.ac/institutes/grid.17063.33", 
              "name": [
                "University of Toronto, 399 Bathurst Street, Room 1E-410B, M5T 2S8, Toronto, Ontario, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Gladman", 
            "givenName": "Dafna D", 
            "id": "sg:person.01136132356.43", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136132356.43"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Swedish Medical Center", 
              "id": "https://www.grid.ac/institutes/grid.281044.b", 
              "name": [
                "Swedish Medical Center, 1101 Madison Street, Suite 1000, 98104, Seattle, WA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Mease", 
            "givenName": "Philip J", 
            "id": "sg:person.012234527537.40", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012234527537.40"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "King's College London", 
              "id": "https://www.grid.ac/institutes/grid.13097.3c", 
              "name": [
                "King's College, Strand, Denmark Hill Campus, WC2R 2LS, London, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Choy", 
            "givenName": "Ernest HS", 
            "id": "sg:person.01345733561.44", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01345733561.44"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University of Rochester", 
              "id": "https://www.grid.ac/institutes/grid.16416.34", 
              "name": [
                "University of Rochester, 601 Elmwood Avenue, 14642, Rochester, NY, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ritchlin", 
            "givenName": "Christopher T", 
            "id": "sg:person.01253702202.22", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01253702202.22"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Abbott (United States)", 
              "id": "https://www.grid.ac/institutes/grid.417574.4", 
              "name": [
                "Abbott Laboratories, 100 Abbott Park Road, 60064-3500, Abbott Park, IL, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Perdok", 
            "givenName": "Renee J", 
            "id": "sg:person.01045404105.12", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01045404105.12"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Abbott (United States)", 
              "id": "https://www.grid.ac/institutes/grid.417574.4", 
              "name": [
                "Abbott Laboratories, 100 Abbott Park Road, 60064-3500, Abbott Park, IL, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Sasso", 
            "givenName": "Eric H", 
            "id": "sg:person.01113517305.60", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113517305.60"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "https://doi.org/10.1111/j.0105-2896.2005.00338.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001014564"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/1529-0131(199806)41:6<1103::aid-art18>3.0.co;2-n", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1002822347"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1136/ard.2005.045658", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1003241454"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1517/13543784.9.7.1511", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007093639"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/art.21678", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008387845"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/art.21678", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008387845"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/art.22143", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009080333"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/rheumatology/keg384", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012652160"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/978-0-387-68566-3_8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014508351", 
              "https://doi.org/10.1007/978-0-387-68566-3_8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/978-0-387-68566-3_8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014508351", 
              "https://doi.org/10.1007/978-0-387-68566-3_8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/art.21306", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017063818"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/art.21306", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017063818"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1136/ard.2004.034157", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018096031"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/rheumatology/keg217", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021838438"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/art.22379", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027145057"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1136/ard.2008.092767", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030393517"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1053/sarh.2002.50024", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033426113"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/art.23945", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035650388"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/art.20335", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036798091"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/art.22800", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040719076"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1136/ard.62.1.68", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041727619"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1136/ard.2006.056457", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048498861"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/art.21519", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049214196"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/art.21519", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049214196"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/art.22805", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050507563"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/rheumatology/30.4.245", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1060009730"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1172/jci16069", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1063416205"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.3899/jrheum.081018", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1071541658"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1079881724", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1083034523", 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2010-06", 
        "datePublishedReg": "2010-06-01", 
        "description": "INTRODUCTION: To identify independent predictors of radiographic progression in psoriatic arthritis (PsA) for patients treated with adalimumab or placebo in the Adalimumab Effectiveness in PsA Trial (ADEPT).\nMETHODS: Univariate analyses and multivariate linear regression analyses assessed risk for radiographic progression (change in modified total Sharp score, DeltamTSS>0.5) from baseline to week 24 for C-reactive protein (CRP) and other baseline variables, and for 24-week time-averaged CRP (univariate analysis only). Subanalyses determined mean DeltamTSS for CRP subgroups. Analyses were post hoc, with observed data.\nRESULTS: One hundred and forty-four adalimumab-treated patients and 152 placebo-treated patients were assessed. Mean CRP was 64% lower by week 2 with adalimumab and essentially unchanged with placebo. Univariate analyses indicated that elevated CRP at baseline and time-averaged CRP were strongly associated with radiographic progression for placebo-treated patients but not for adalimumab-treated patients. Multivariate analysis confirmed that elevated baseline CRP was the only strong independent risk factor for radiographic progression (for CRP>or=1.0 mg/dl: odds ratio=3.28, 95% confidence interval=1.66 to 6.51, P<0.001). Adalimumab treatment reduced risk of progression approximately fivefold. The difference between mean DeltamTSS for adalimumab versus placebo was greatest for patients with baseline CRP>or=2.0 mg/dl (-0.5 vs. 2.6).\nCONCLUSIONS: Systemic inflammation in PsA, as indicated by elevated baseline CRP, was the only strong independent predictor of radiographic progression. This association was observed predominantly for placebo-treated patients. Adalimumab treatment substantially reduced the overall risk of radiographic progression, and provided greatest radiographic benefit for patients with the greatest CRP concentrations at baseline.\nTRIAL REGISTRATION: Trial registration: NCT00195689.", 
        "genre": "research_article", 
        "id": "sg:pub.10.1186/ar3049", 
        "inLanguage": [
          "en"
        ], 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1297499", 
            "issn": [
              "1478-6354", 
              "1478-6362"
            ], 
            "name": "Arthritis Research & Therapy", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "3", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "12"
          }
        ], 
        "name": "Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT", 
        "pagination": "r113", 
        "productId": [
          {
            "name": "readcube_id", 
            "type": "PropertyValue", 
            "value": [
              "3fe1dfc2907884950ac06db8079adf0d3123c62c3f57f5c7a94e3b72eaa20ba7"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "20537151"
            ]
          }, 
          {
            "name": "nlm_unique_id", 
            "type": "PropertyValue", 
            "value": [
              "101154438"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1186/ar3049"
            ]
          }, 
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1013409774"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1186/ar3049", 
          "https://app.dimensions.ai/details/publication/pub.1013409774"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2019-04-10T22:31", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8690_00000511.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "http://link.springer.com/10.1186%2Far3049"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/ar3049'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/ar3049'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/ar3049'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/ar3049'


     

    This table displays all metadata directly associated to this object as RDF triples.

    265 TRIPLES      21 PREDICATES      73 URIs      39 LITERALS      27 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1186/ar3049 schema:about N11b948b21d93448887e4852372e411ba
    2 N1dcd02ccb3994268bd7912385b23ddd0
    3 N33aee611018d4491a603e1a1a1820009
    4 N4fd9cd0537ae4173909b74417f09eb15
    5 N505a9c6b0aef4a268042cadd15d5b887
    6 N595d8897e28240f7b194624bac83a4c2
    7 N59c3b2b4f89940f6a092cd3113ece45a
    8 N6c03da1774194bd59116c4f86eccbaeb
    9 N749e7e3a425445debffff6d9eccd2e52
    10 N75a9fe64124542bc97eb20350b4509ef
    11 N7e97c982d31e435095e1f5e9fc24d2e3
    12 N7ee2d73044414fe28658473f2771be6b
    13 Nb49bff7b03734b899b47d246e15dc577
    14 Nc3f7e3eba26b4090bb20e5e782ef88f1
    15 Nc70c0863855e4239b9622014537453e2
    16 Nd29bf3816e7648ac983a8e361115cf79
    17 Nd81f6b28131a4f998d94279646b0d8d4
    18 Nff6d5f58b56040e2962be23d56abcea7
    19 anzsrc-for:11
    20 anzsrc-for:1103
    21 schema:author N235d126b0e4a4940a6e82327c73fbc86
    22 schema:citation sg:pub.10.1007/978-0-387-68566-3_8
    23 https://app.dimensions.ai/details/publication/pub.1079881724
    24 https://app.dimensions.ai/details/publication/pub.1083034523
    25 https://doi.org/10.1002/1529-0131(199806)41:6<1103::aid-art18>3.0.co;2-n
    26 https://doi.org/10.1002/art.20335
    27 https://doi.org/10.1002/art.21306
    28 https://doi.org/10.1002/art.21519
    29 https://doi.org/10.1002/art.21678
    30 https://doi.org/10.1002/art.22143
    31 https://doi.org/10.1002/art.22379
    32 https://doi.org/10.1002/art.22800
    33 https://doi.org/10.1002/art.22805
    34 https://doi.org/10.1002/art.23945
    35 https://doi.org/10.1053/sarh.2002.50024
    36 https://doi.org/10.1093/rheumatology/30.4.245
    37 https://doi.org/10.1093/rheumatology/keg217
    38 https://doi.org/10.1093/rheumatology/keg384
    39 https://doi.org/10.1111/j.0105-2896.2005.00338.x
    40 https://doi.org/10.1136/ard.2004.034157
    41 https://doi.org/10.1136/ard.2005.045658
    42 https://doi.org/10.1136/ard.2006.056457
    43 https://doi.org/10.1136/ard.2008.092767
    44 https://doi.org/10.1136/ard.62.1.68
    45 https://doi.org/10.1172/jci16069
    46 https://doi.org/10.1517/13543784.9.7.1511
    47 https://doi.org/10.3899/jrheum.081018
    48 schema:datePublished 2010-06
    49 schema:datePublishedReg 2010-06-01
    50 schema:description INTRODUCTION: To identify independent predictors of radiographic progression in psoriatic arthritis (PsA) for patients treated with adalimumab or placebo in the Adalimumab Effectiveness in PsA Trial (ADEPT). METHODS: Univariate analyses and multivariate linear regression analyses assessed risk for radiographic progression (change in modified total Sharp score, DeltamTSS>0.5) from baseline to week 24 for C-reactive protein (CRP) and other baseline variables, and for 24-week time-averaged CRP (univariate analysis only). Subanalyses determined mean DeltamTSS for CRP subgroups. Analyses were post hoc, with observed data. RESULTS: One hundred and forty-four adalimumab-treated patients and 152 placebo-treated patients were assessed. Mean CRP was 64% lower by week 2 with adalimumab and essentially unchanged with placebo. Univariate analyses indicated that elevated CRP at baseline and time-averaged CRP were strongly associated with radiographic progression for placebo-treated patients but not for adalimumab-treated patients. Multivariate analysis confirmed that elevated baseline CRP was the only strong independent risk factor for radiographic progression (for CRP>or=1.0 mg/dl: odds ratio=3.28, 95% confidence interval=1.66 to 6.51, P<0.001). Adalimumab treatment reduced risk of progression approximately fivefold. The difference between mean DeltamTSS for adalimumab versus placebo was greatest for patients with baseline CRP>or=2.0 mg/dl (-0.5 vs. 2.6). CONCLUSIONS: Systemic inflammation in PsA, as indicated by elevated baseline CRP, was the only strong independent predictor of radiographic progression. This association was observed predominantly for placebo-treated patients. Adalimumab treatment substantially reduced the overall risk of radiographic progression, and provided greatest radiographic benefit for patients with the greatest CRP concentrations at baseline. TRIAL REGISTRATION: Trial registration: NCT00195689.
    51 schema:genre research_article
    52 schema:inLanguage en
    53 schema:isAccessibleForFree true
    54 schema:isPartOf N926eb82b38cf44a0ac583c0573a4743a
    55 Nd8bf3e74d3bd441cb6f53d2f4d7d06a7
    56 sg:journal.1297499
    57 schema:name Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT
    58 schema:pagination r113
    59 schema:productId N3a17035ed3da4672a8a708f708d4a1a6
    60 N69f3566f2174485499d9e983d8b6ab19
    61 N876023c4fb4c468f921376007712c9b6
    62 Nec72d3f2277549cdbd697301bfcd42de
    63 Nf04864b637f54182b9a61fffd8f9814f
    64 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013409774
    65 https://doi.org/10.1186/ar3049
    66 schema:sdDatePublished 2019-04-10T22:31
    67 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    68 schema:sdPublisher N5e27842dd43e45aea9a19c7bf55aada1
    69 schema:url http://link.springer.com/10.1186%2Far3049
    70 sgo:license sg:explorer/license/
    71 sgo:sdDataset articles
    72 rdf:type schema:ScholarlyArticle
    73 N0204d100d20b471da945e448d2acb88a rdf:first sg:person.01113517305.60
    74 rdf:rest rdf:nil
    75 N11b948b21d93448887e4852372e411ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    76 schema:name Humans
    77 rdf:type schema:DefinedTerm
    78 N1dcd02ccb3994268bd7912385b23ddd0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    79 schema:name Female
    80 rdf:type schema:DefinedTerm
    81 N235d126b0e4a4940a6e82327c73fbc86 rdf:first sg:person.01136132356.43
    82 rdf:rest N6d9e94ee6d0045adbab63d99cc81217b
    83 N33aee611018d4491a603e1a1a1820009 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    84 schema:name Adalimumab
    85 rdf:type schema:DefinedTerm
    86 N3a17035ed3da4672a8a708f708d4a1a6 schema:name doi
    87 schema:value 10.1186/ar3049
    88 rdf:type schema:PropertyValue
    89 N4fd9cd0537ae4173909b74417f09eb15 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    90 schema:name Linear Models
    91 rdf:type schema:DefinedTerm
    92 N505a9c6b0aef4a268042cadd15d5b887 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    93 schema:name Antibodies, Monoclonal, Humanized
    94 rdf:type schema:DefinedTerm
    95 N595d8897e28240f7b194624bac83a4c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    96 schema:name Risk Factors
    97 rdf:type schema:DefinedTerm
    98 N59c3b2b4f89940f6a092cd3113ece45a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    99 schema:name Middle Aged
    100 rdf:type schema:DefinedTerm
    101 N5e27842dd43e45aea9a19c7bf55aada1 schema:name Springer Nature - SN SciGraph project
    102 rdf:type schema:Organization
    103 N69f3566f2174485499d9e983d8b6ab19 schema:name pubmed_id
    104 schema:value 20537151
    105 rdf:type schema:PropertyValue
    106 N6c03da1774194bd59116c4f86eccbaeb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    107 schema:name Radiography
    108 rdf:type schema:DefinedTerm
    109 N6d9e94ee6d0045adbab63d99cc81217b rdf:first sg:person.012234527537.40
    110 rdf:rest N93870fd04fae4d9db4f12794cff9bc9b
    111 N749e7e3a425445debffff6d9eccd2e52 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    112 schema:name Double-Blind Method
    113 rdf:type schema:DefinedTerm
    114 N75a9fe64124542bc97eb20350b4509ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    115 schema:name Treatment Outcome
    116 rdf:type schema:DefinedTerm
    117 N7e97c982d31e435095e1f5e9fc24d2e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    118 schema:name Adult
    119 rdf:type schema:DefinedTerm
    120 N7ee2d73044414fe28658473f2771be6b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    121 schema:name Antibodies, Monoclonal
    122 rdf:type schema:DefinedTerm
    123 N876023c4fb4c468f921376007712c9b6 schema:name dimensions_id
    124 schema:value pub.1013409774
    125 rdf:type schema:PropertyValue
    126 N926eb82b38cf44a0ac583c0573a4743a schema:volumeNumber 12
    127 rdf:type schema:PublicationVolume
    128 N93870fd04fae4d9db4f12794cff9bc9b rdf:first sg:person.01345733561.44
    129 rdf:rest Nee2224ca89e24feb9551e584572ecd9d
    130 Nb49bff7b03734b899b47d246e15dc577 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    131 schema:name Male
    132 rdf:type schema:DefinedTerm
    133 Nc3f7e3eba26b4090bb20e5e782ef88f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    134 schema:name Multivariate Analysis
    135 rdf:type schema:DefinedTerm
    136 Nc70c0863855e4239b9622014537453e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    137 schema:name Antirheumatic Agents
    138 rdf:type schema:DefinedTerm
    139 Nd29bf3816e7648ac983a8e361115cf79 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    140 schema:name Arthritis, Psoriatic
    141 rdf:type schema:DefinedTerm
    142 Nd81f6b28131a4f998d94279646b0d8d4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    143 schema:name Disease Progression
    144 rdf:type schema:DefinedTerm
    145 Nd8bf3e74d3bd441cb6f53d2f4d7d06a7 schema:issueNumber 3
    146 rdf:type schema:PublicationIssue
    147 Ne480be7400c247aaa2b83db960d73269 rdf:first sg:person.01045404105.12
    148 rdf:rest N0204d100d20b471da945e448d2acb88a
    149 Nec72d3f2277549cdbd697301bfcd42de schema:name nlm_unique_id
    150 schema:value 101154438
    151 rdf:type schema:PropertyValue
    152 Nee2224ca89e24feb9551e584572ecd9d rdf:first sg:person.01253702202.22
    153 rdf:rest Ne480be7400c247aaa2b83db960d73269
    154 Nf04864b637f54182b9a61fffd8f9814f schema:name readcube_id
    155 schema:value 3fe1dfc2907884950ac06db8079adf0d3123c62c3f57f5c7a94e3b72eaa20ba7
    156 rdf:type schema:PropertyValue
    157 Nff6d5f58b56040e2962be23d56abcea7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    158 schema:name C-Reactive Protein
    159 rdf:type schema:DefinedTerm
    160 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    161 schema:name Medical and Health Sciences
    162 rdf:type schema:DefinedTerm
    163 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    164 schema:name Clinical Sciences
    165 rdf:type schema:DefinedTerm
    166 sg:journal.1297499 schema:issn 1478-6354
    167 1478-6362
    168 schema:name Arthritis Research & Therapy
    169 rdf:type schema:Periodical
    170 sg:person.01045404105.12 schema:affiliation https://www.grid.ac/institutes/grid.417574.4
    171 schema:familyName Perdok
    172 schema:givenName Renee J
    173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01045404105.12
    174 rdf:type schema:Person
    175 sg:person.01113517305.60 schema:affiliation https://www.grid.ac/institutes/grid.417574.4
    176 schema:familyName Sasso
    177 schema:givenName Eric H
    178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113517305.60
    179 rdf:type schema:Person
    180 sg:person.01136132356.43 schema:affiliation https://www.grid.ac/institutes/grid.17063.33
    181 schema:familyName Gladman
    182 schema:givenName Dafna D
    183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136132356.43
    184 rdf:type schema:Person
    185 sg:person.012234527537.40 schema:affiliation https://www.grid.ac/institutes/grid.281044.b
    186 schema:familyName Mease
    187 schema:givenName Philip J
    188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012234527537.40
    189 rdf:type schema:Person
    190 sg:person.01253702202.22 schema:affiliation https://www.grid.ac/institutes/grid.16416.34
    191 schema:familyName Ritchlin
    192 schema:givenName Christopher T
    193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01253702202.22
    194 rdf:type schema:Person
    195 sg:person.01345733561.44 schema:affiliation https://www.grid.ac/institutes/grid.13097.3c
    196 schema:familyName Choy
    197 schema:givenName Ernest HS
    198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01345733561.44
    199 rdf:type schema:Person
    200 sg:pub.10.1007/978-0-387-68566-3_8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014508351
    201 https://doi.org/10.1007/978-0-387-68566-3_8
    202 rdf:type schema:CreativeWork
    203 https://app.dimensions.ai/details/publication/pub.1079881724 schema:CreativeWork
    204 https://app.dimensions.ai/details/publication/pub.1083034523 schema:CreativeWork
    205 https://doi.org/10.1002/1529-0131(199806)41:6<1103::aid-art18>3.0.co;2-n schema:sameAs https://app.dimensions.ai/details/publication/pub.1002822347
    206 rdf:type schema:CreativeWork
    207 https://doi.org/10.1002/art.20335 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036798091
    208 rdf:type schema:CreativeWork
    209 https://doi.org/10.1002/art.21306 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017063818
    210 rdf:type schema:CreativeWork
    211 https://doi.org/10.1002/art.21519 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049214196
    212 rdf:type schema:CreativeWork
    213 https://doi.org/10.1002/art.21678 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008387845
    214 rdf:type schema:CreativeWork
    215 https://doi.org/10.1002/art.22143 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009080333
    216 rdf:type schema:CreativeWork
    217 https://doi.org/10.1002/art.22379 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027145057
    218 rdf:type schema:CreativeWork
    219 https://doi.org/10.1002/art.22800 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040719076
    220 rdf:type schema:CreativeWork
    221 https://doi.org/10.1002/art.22805 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050507563
    222 rdf:type schema:CreativeWork
    223 https://doi.org/10.1002/art.23945 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035650388
    224 rdf:type schema:CreativeWork
    225 https://doi.org/10.1053/sarh.2002.50024 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033426113
    226 rdf:type schema:CreativeWork
    227 https://doi.org/10.1093/rheumatology/30.4.245 schema:sameAs https://app.dimensions.ai/details/publication/pub.1060009730
    228 rdf:type schema:CreativeWork
    229 https://doi.org/10.1093/rheumatology/keg217 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021838438
    230 rdf:type schema:CreativeWork
    231 https://doi.org/10.1093/rheumatology/keg384 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012652160
    232 rdf:type schema:CreativeWork
    233 https://doi.org/10.1111/j.0105-2896.2005.00338.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1001014564
    234 rdf:type schema:CreativeWork
    235 https://doi.org/10.1136/ard.2004.034157 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018096031
    236 rdf:type schema:CreativeWork
    237 https://doi.org/10.1136/ard.2005.045658 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003241454
    238 rdf:type schema:CreativeWork
    239 https://doi.org/10.1136/ard.2006.056457 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048498861
    240 rdf:type schema:CreativeWork
    241 https://doi.org/10.1136/ard.2008.092767 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030393517
    242 rdf:type schema:CreativeWork
    243 https://doi.org/10.1136/ard.62.1.68 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041727619
    244 rdf:type schema:CreativeWork
    245 https://doi.org/10.1172/jci16069 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063416205
    246 rdf:type schema:CreativeWork
    247 https://doi.org/10.1517/13543784.9.7.1511 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007093639
    248 rdf:type schema:CreativeWork
    249 https://doi.org/10.3899/jrheum.081018 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071541658
    250 rdf:type schema:CreativeWork
    251 https://www.grid.ac/institutes/grid.13097.3c schema:alternateName King's College London
    252 schema:name King's College, Strand, Denmark Hill Campus, WC2R 2LS, London, UK
    253 rdf:type schema:Organization
    254 https://www.grid.ac/institutes/grid.16416.34 schema:alternateName University of Rochester
    255 schema:name University of Rochester, 601 Elmwood Avenue, 14642, Rochester, NY, USA
    256 rdf:type schema:Organization
    257 https://www.grid.ac/institutes/grid.17063.33 schema:alternateName University of Toronto
    258 schema:name University of Toronto, 399 Bathurst Street, Room 1E-410B, M5T 2S8, Toronto, Ontario, Canada
    259 rdf:type schema:Organization
    260 https://www.grid.ac/institutes/grid.281044.b schema:alternateName Swedish Medical Center
    261 schema:name Swedish Medical Center, 1101 Madison Street, Suite 1000, 98104, Seattle, WA, USA
    262 rdf:type schema:Organization
    263 https://www.grid.ac/institutes/grid.417574.4 schema:alternateName Abbott (United States)
    264 schema:name Abbott Laboratories, 100 Abbott Park Road, 60064-3500, Abbott Park, IL, USA
    265 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...